# Prime Medicine (PRME) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PRME
## Company Profile
- Ticker: PRME
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 3.32 USD
- Market cap: 579782017.71 USD
- Last updated: 2026-10-13
## Business Overview
### Prime Editing
Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo.
### PM577
PM577 is an in vivo Prime Editing candidate designed to correct disease-causing mutations in the liver for Wilson disease.
### PM647
PM647 is an in vivo liver-directed program for alpha-1 antitrypsin deficiency and is approaching clinical development on a timeline similar to PM577.
### Chronic Granulomatous Disease
PM359 is an ex vivo edited cell therapy for chronic granulomatous disease. Prime Medicine is continuing regulatory dialogue with the FDA regarding a potential BLA path.
## Why The Stock Is Moving

As of Oct 13, 2026, PRME closed down 8.03% at $3.32. No new same-company headline was identified in the current news window.

## Future Catalysts

- IND and/or CTA submission for PM577 in Wilson disease in the first half of 2026.
- IND and/or CTA submission for PM647 in alpha-1 antitrypsin deficiency around mid-2026.
- Initial clinical data from PM577 and PM647 in 2027.

## Recent News
- 2026-10-05 11:59 EST — [Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease](https://biopharmsignal.com/news/PRME/prime-medicine-announces-first-patient-dosed-in-global-phase-1-2-clinical-trial--902cfa4c) — Source: Prime Medicine
- 2026-09-24 20:01 EST — [Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency](https://biopharmsignal.com/news/PRME/prime-medicine-announces-u-s-fda-clearance-of-investigational-new-drug-applicati-b1546925) — Source: Prime Medicine
- 2026-09-03 12:00 EST — [Prime Medicine to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences-6f4b8eba) — Source: Prime Medicine
- 2026-08-06 12:00 EST — [Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/PRME/prime-medicine-reports-second-quarter-2026-financial-results-and-provides-busine-1fa9eea6) — Source: Prime Medicine
- 2026-07-23 20:05 EST — [Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease](https://biopharmsignal.com/news/PRME/prime-medicine-announces-u-s-fda-clearance-of-investigational-new-drug-applicati-fad1ff80) — Source: Prime Medicine